Açık Akademik Arşiv Sistemi

Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

Ramazan Idilman; Mehmet Demir; Murat Aladag; Cihan Erol; Bilger Cavus; Raim Iliaz; Hayrettin Koklu; Yilmaz Cakaloglu; Memduh Sahin; Galip Ersoz; Iftihar Koksal; Zeki Karasu; Meric Ozgenel; Ilker Turan; Feyza Gunduz; Huseyin Ataseven; Meral Akdogan; Murat Kiyici; Köksal, Aydın Şeref; Sila Akhan; Fulya Gunsar; Fehmi Tabak; Sabahattin Kaymakoglu; Ulus S. Akarca; Mesut Akarsu; Huseyin Alkim; Filiz Araz; Fehmi Ates; Bilgehan Aygen; Ismail Balik; Huseyin S. Barut; Birol Baysal; Aylin Bolat; Ilhami Celik; Suleyman Cosgun; Fatih Ensaroglu; Hale Gokcan; Selim Gurel; Sebnem Gursoy; Ahmet Cagan Inkaya; Cemil Kamilli; Taylan Kav; Ziya Kuruuzum; Fatih O. Onder; Necati Ormeci; Omer Ozbakir; Seren Ozenirler; Birol Ozer; Hasan Ozkan; Sule Poturoglu; Ebubekir Senates; Halis Simsek; Toka, Bilal; Hakan Unal; Serkan Yaras; Abdullah E. Yildirim; Beytullah Yildirim; Bulent Yilmaz; Hasan Yilmaz; Ahmet Yozgat; Cihan Yurdaydin
URI: https://doi.org/10.1111/jvh.13075
https://hdl.handle.net/20.500.12619/66082
Date: 2019

Abstract:

Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.

Show full item record

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)